BRANCHINI, Alessio
BRANCHINI, Alessio
Dipartimento di Scienze della vita e biotecnologie
1,3,8-Triazaspiro[4.5]decane Derivatives Inhibit Permeability Transition Pores through a FO-ATP Synthase c Subunit Glu119-Independent Mechanism That Prevents Oligomycin A-Related Side Effects
2023 Pedriali, G.; Ramaccini, D.; Bouhamida, E.; Branchini, A.; Turrin, G.; Tonet, E.; Scala, A.; Patergnani, S.; Pinotti, M.; Trapella, C.; Giorgi, C.; Tremoli, E.; Campo, G.; Morciano, G.; Pinton, P.
A factor X variant with engineered activation peptide as innovative by-passing agent for haemophilia
file con accesso da definire2022 Tonetto, E.; Tarantino, R.; Testa, M. F.; Peretto, L.; Bernardi, F.; Pinotti, M.; Branchini, A.
A new type 1 von Willebrand Disease (VWD) characterized by increased clearance of von Willebrand Factor (VWF) due to the heterozygous p.P1127S mutation: clinical phenotype and pathogenic mechanisms
file con accesso da definire2022 M. Sacco, M. Tardugno; De Cristofaro, R.; Lancellotti, S.; Bernardi, F.; Pinotti, M.; Branchini, A.; Giusti, B.; Castaman, G.
A next-generation rFVIIa fusion protein with enhanced half-life as a novel by-passing tool in hemophilia
2020 Branchini, Alessio; Ferrarese, Mattia; Nilsen, Jeannette; Bern, Malin; Davidson, Robert J.; Camire, Rodney M.; Roopenian, Derry C.; Sandlie, Inger; Lombardi, Silvia; Terje Andersen, Jan; Pinotti, Mirko
A novel tailored correction approach for recurrent hemophilia-causing nonsense mutations through AntiCodon-Engineered suppressor tRNAs
file con accesso da definire2023 Testa, Maria Francesca; Bernardi, Francesco; Pinotti, Mirko; Branchini, Alessio
A recoded view on the F9 p.Cys178Ter pathogenic mechanism
2020 Branchini, A.; Pinotti, M.
A strategy with chaperone-like compounds to restore expression of factor IX variants affected by frequent missense mutations causing hemophilia B
2018 Pignani, Silvia; Todaro, Alice; Ferrarese, Mattia; Marchi, Saverio; Lombardi, Silvia; Balestra, Dario; Pinton, Paolo; Bernardi, Francesco; Pinotti, Mirko; Branchini, Alessio
Academic Editor per la rivista PLoS One
file con accesso da definire2020 Branchini, Alessio
Activated factor VII-antithrombin complex predicts mortality in patients with stable coronary artery disease: a cohort study
2016 Martinelli, N; Girelli, D; Baroni, Marcello; Guarini, P; Sandri, M; Lunghi, Barbara; Tosi, F; Branchini, Alessio; Sartori, F; Woodhams, B; Bernardi, Francesco; Olivieri, O.
Activated factor VII: antithrombin complex plasma concentration in subjects with or without angiographically demonstrated coronary artery disease and myocardial infarction
file con accesso da definire2013 F., Tosi; N., Martinelli; Baroni, Marcello; P., Guarini; S., Udali; Branchini, Alessio; B., Woodhams; Bernardi, Francesco; O., Olivieri
Activation of a cryptic splice site in a potentially lethal coagulation defect accounts for a functional protein variant
file con accesso da definire2012 Cavallari, Nicola; Balestra, Dario; Branchini, Alessio; Maestri, Iva; Chuamsunrit, A; Sasanakul, W; Mariani, G; Pagani, F; Bernardi, Francesco; Pinotti, Mirko
Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca 2+ levels and tumor growth
2019 Marchi, Saverio; Corricelli, Mariangela; Branchini, Alessio; Vitto, VERONICA ANGELA MARIA; Missiroli, Sonia; Morciano, Giampaolo; Perrone, Mariasole; Ferrarese, Mattia; Giorgi, Carlotta; Pinotti, Mirko; Galluzzi, Lorenzo; Kroemer, Guido; Pinton, Paolo
An Altered Splicing Registry Explains the Differential ExSpeU1-Mediated Rescue of Splicing Mutations Causing Haemophilia A
2019 Balestra, Dario; Maestri, Iva; Branchini, Alessio; Ferrarese, Mattia; Bernardi, Francesco; Pinotti, Mirko
An engineered factor X variant as a novel by-passing agent for hemophilia
file con accesso da definire2022 Tonetto, Elena; Testa, Maria Francesca; Tarantino, Rebecca; Peretto, Laura; Pinotti, Mirko; Branchini, Alessio
An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics
2020 Bern, M.; Nilsen, J.; Ferrarese, M.; Sand, K. M. K.; Gjolberg, T. T.; Lode, H. E.; Davidson, R. J.; Camire, R. M.; Baekkevold, E. S.; Foss, S.; Grevys, A.; Dalhus, B.; Wilson, J.; Hoydahl, L. S.; Christianson, G. J.; Roopenian, D. C.; Schlothauer, T.; Michaelsen, T. E.; Moe, M. C.; Lombardi, S.; Pinotti, M.; Sandlie, I.; Branchini, A.; Andersen, J. T.
An engineered tale-transcription factor rescues transcription of factor VII impaired by promoter mutations and enhances its endogenous expression in hepatocytes
2016 Barbon, Elena; Pignani, Silvia; Branchini, Alessio; Bernardi, Francesco; Pinotti, Mirko; Bovolenta, Matteo
An exon-specific small nuclear u1 rna (Exspeu1) improves hepatic otc expression in a splicing-defective spf /ash mouse model of ornithine transcarbamylase deficiency
2020 Balestra, D.; Ferrarese, M.; Lombardi, S.; Ziliotto, N.; Branchini, A.; Petersen, N.; Bosma, P.; Pinotti, M.; van de Graaf, S. F. J.
An integrated multi-tool analysis contributes elements to interpreting unclassified factor IX missense variants associated with haemophilia B
file con accesso da definire2024 Sacco, Monica; Testa, Maria Francesca; Ferretti, Antonietta; Basso, Maria; Lancellotti, Stefano; Tardugno, Maira; Di Gennaro, Leonardo; Concolino, Paola; Minucci, Angelo; Spoliti, Claudia; Branchini, Alessio; De Cristofaro, Raimondo
An optimized in vitro expression platform identifies Haemophilia B nonsense mutations, and thus patients, eligible for therapeutic drug-induced readthrough
2017 Branchini, Alessio; Ferrarese, Mattia; Castaman, Giancarlo; Bernardi, Francesco; Pinotti, Mirko
Associate Editor della rivista Frontiers in Molecular Biosciences - sezione Molecular Diagnostics and Therapeutics
file con accesso da definire2024 Branchini, Alessio
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| 1,3,8-Triazaspiro[4.5]decane Derivatives Inhibit Permeability Transition Pores through a FO-ATP Synthase c Subunit Glu119-Independent Mechanism That Prevents Oligomycin A-Related Side Effects | 2023 | Pedriali, G.; Ramaccini, D.; Bouhamida, E.; Branchini, A.; Turrin, G.; Tonet, E.; Scala, A.; Pate...rgnani, S.; Pinotti, M.; Trapella, C.; Giorgi, C.; Tremoli, E.; Campo, G.; Morciano, G.; Pinton, P. | |
| A factor X variant with engineered activation peptide as innovative by-passing agent for haemophilia | 2022 | Tonetto, E.; Tarantino, R.; Testa, M. F.; Peretto, L.; Bernardi, F.; Pinotti, M.; Branchini, A. | file con accesso da definire |
| A new type 1 von Willebrand Disease (VWD) characterized by increased clearance of von Willebrand Factor (VWF) due to the heterozygous p.P1127S mutation: clinical phenotype and pathogenic mechanisms | 2022 | M. Sacco, M. Tardugno; De Cristofaro, R.; Lancellotti, S.; Bernardi, F.; Pinotti, M.; Branchini, ...A.; Giusti, B.; Castaman, G. | file con accesso da definire |
| A next-generation rFVIIa fusion protein with enhanced half-life as a novel by-passing tool in hemophilia | 2020 | Branchini, Alessio; Ferrarese, Mattia; Nilsen, Jeannette; Bern, Malin; Davidson, Robert J.; Camir...e, Rodney M.; Roopenian, Derry C.; Sandlie, Inger; Lombardi, Silvia; Terje Andersen, Jan; Pinotti, Mirko | |
| A novel tailored correction approach for recurrent hemophilia-causing nonsense mutations through AntiCodon-Engineered suppressor tRNAs | 2023 | Testa, Maria Francesca; Bernardi, Francesco; Pinotti, Mirko; Branchini, Alessio | file con accesso da definire |
| A recoded view on the F9 p.Cys178Ter pathogenic mechanism | 2020 | Branchini, A.; Pinotti, M. | |
| A strategy with chaperone-like compounds to restore expression of factor IX variants affected by frequent missense mutations causing hemophilia B | 2018 | Pignani, Silvia; Todaro, Alice; Ferrarese, Mattia; Marchi, Saverio; Lombardi, Silvia; Balestra, D...ario; Pinton, Paolo; Bernardi, Francesco; Pinotti, Mirko; Branchini, Alessio | |
| Academic Editor per la rivista PLoS One | 2020 | Branchini, Alessio | file con accesso da definire |
| Activated factor VII-antithrombin complex predicts mortality in patients with stable coronary artery disease: a cohort study | 2016 | Martinelli, N; Girelli, D; Baroni, Marcello; Guarini, P; Sandri, M; Lunghi, Barbara; Tosi, F; Bra...nchini, Alessio; Sartori, F; Woodhams, B; Bernardi, Francesco; Olivieri, O. | |
| Activated factor VII: antithrombin complex plasma concentration in subjects with or without angiographically demonstrated coronary artery disease and myocardial infarction | 2013 | F., Tosi; N., Martinelli; Baroni, Marcello; P., Guarini; S., Udali; Branchini, Alessio; B., Woodh...ams; Bernardi, Francesco; O., Olivieri | file con accesso da definire |
| Activation of a cryptic splice site in a potentially lethal coagulation defect accounts for a functional protein variant | 2012 | Cavallari, Nicola; Balestra, Dario; Branchini, Alessio; Maestri, Iva; Chuamsunrit, A; Sasanakul, ...W; Mariani, G; Pagani, F; Bernardi, Francesco; Pinotti, Mirko | file con accesso da definire |
| Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca 2+ levels and tumor growth | 2019 | Marchi, Saverio; Corricelli, Mariangela; Branchini, Alessio; Vitto, VERONICA ANGELA MARIA; Missir...oli, Sonia; Morciano, Giampaolo; Perrone, Mariasole; Ferrarese, Mattia; Giorgi, Carlotta; Pinotti, Mirko; Galluzzi, Lorenzo; Kroemer, Guido; Pinton, Paolo | |
| An Altered Splicing Registry Explains the Differential ExSpeU1-Mediated Rescue of Splicing Mutations Causing Haemophilia A | 2019 | Balestra, Dario; Maestri, Iva; Branchini, Alessio; Ferrarese, Mattia; Bernardi, Francesco; Pinott...i, Mirko | |
| An engineered factor X variant as a novel by-passing agent for hemophilia | 2022 | Tonetto, Elena; Testa, Maria Francesca; Tarantino, Rebecca; Peretto, Laura; Pinotti, Mirko; Branc...hini, Alessio | file con accesso da definire |
| An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics | 2020 | Bern, M.; Nilsen, J.; Ferrarese, M.; Sand, K. M. K.; Gjolberg, T. T.; Lode, H. E.; Davidson, R. J....; Camire, R. M.; Baekkevold, E. S.; Foss, S.; Grevys, A.; Dalhus, B.; Wilson, J.; Hoydahl, L. S.; Christianson, G. J.; Roopenian, D. C.; Schlothauer, T.; Michaelsen, T. E.; Moe, M. C.; Lombardi, S.; Pinotti, M.; Sandlie, I.; Branchini, A.; Andersen, J. T. | |
| An engineered tale-transcription factor rescues transcription of factor VII impaired by promoter mutations and enhances its endogenous expression in hepatocytes | 2016 | Barbon, Elena; Pignani, Silvia; Branchini, Alessio; Bernardi, Francesco; Pinotti, Mirko; Bovolent...a, Matteo | |
| An exon-specific small nuclear u1 rna (Exspeu1) improves hepatic otc expression in a splicing-defective spf /ash mouse model of ornithine transcarbamylase deficiency | 2020 | Balestra, D.; Ferrarese, M.; Lombardi, S.; Ziliotto, N.; Branchini, A.; Petersen, N.; Bosma, P.; ...Pinotti, M.; van de Graaf, S. F. J. | |
| An integrated multi-tool analysis contributes elements to interpreting unclassified factor IX missense variants associated with haemophilia B | 2024 | Sacco, Monica; Testa, Maria Francesca; Ferretti, Antonietta; Basso, Maria; Lancellotti, Stefano; ...Tardugno, Maira; Di Gennaro, Leonardo; Concolino, Paola; Minucci, Angelo; Spoliti, Claudia; Branchini, Alessio; De Cristofaro, Raimondo | file con accesso da definire |
| An optimized in vitro expression platform identifies Haemophilia B nonsense mutations, and thus patients, eligible for therapeutic drug-induced readthrough | 2017 | Branchini, Alessio; Ferrarese, Mattia; Castaman, Giancarlo; Bernardi, Francesco; Pinotti, Mirko | |
| Associate Editor della rivista Frontiers in Molecular Biosciences - sezione Molecular Diagnostics and Therapeutics | 2024 | Branchini, Alessio | file con accesso da definire |